If this was a drug that was prescribed to prevent weight gain, it might also prevent some proportion of OSA, and there you could argue it will take away some proportion of market share.
From my understanding these drugs are prescribed as treatments for weight loss (and diabetes) rather than to prevent people becoming overweight in the first place.
GLP-1 and OSA, page-8
-
- There are more pages in this discussion • 86 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$35.17 |
Change
-0.270(0.76%) |
Mkt cap ! $22.28B | |||
| Open | High | Low | Value | Volume |
| $35.01 | $35.31 | $35.01 | $27.67M | 787.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4000 | $35.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $35.23 | 3393 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| RMD (ASX) Chart |